US4026290A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of administering medicaments through the skin
Assignee: Fisons Ltd
•
Filing: 1975-11-18
•
Granted: 1977-05-31
•
Expires: 1995-11-18
Abstract
Abstract There are provided means for the extended application of a systemic medicament to the skin of an animal, especially for prophylaxis, which means comprises in combination, a systemic medicament composition containing a carrier which is capable of transmitting the medicament through the skin, and attachment means for contacting the medicament composition with a portion of the skin of the animal.
Inventors
- 👤 Peter John Brooker
- 👤 John Goose
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-22 17:16
CPC Classifications
A; A61; A61D; A61D7/00; A61K; A61K9/00; A61K9/70; A61K9/7023; A61M; A61M37/00
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
87 words
A method of administering a systemically active anthelmintic compound over an extended period to an animal through its skin, which method comprises contacting the skin of the animal with a composition containing the anthelmintic compound and a carrier capable of transmitting the compound through the skin, said composition being contained within one or more depressions provided in the basal surface area of a device having means by which it is attached to the animal such that the basal surface area thereof contacts the skin of the animal.
Claim 2
Independent Claim
87 words
A method of administering a systemically active anthelmintic compound over an extended period to an animal through its skin, which method comprises contacting the skin of the animal with a composition containing the anthelmintic compound and a carrier capable of transmitting the compound through the skin, said composition being contained within one or more depressions provided in the basal surface area of a device having means by which it is attached to the animal such that the basal surface area thereof contacts the skin of the animal.
Claim 3
Dependent Claim
22 words
A method according to claim 1, wherein the rate of transmission of the anthelmintic compound through the skin is propylactic but non-curative.
Claim 4
Dependent Claim
67 words
A method according to claim 1, wherein the anthelmintic compound is selected from the group consisting of: 2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole) or a salt thereof, 2-(4-thiazoly)benzimidazole, carbon tetrachloride, methyl-5-butyl-benzimidazole-2-carbamate 2,2'-methylenebis-(3,4,6-trichlorophenol) or a salt thereof, 2-(2-methoxyethyl)pyridine or a salt thereof, 4-hydroxy-3-iodo-5-nitrobenzonitrile or a salt thereof, 3'-chloro-4'-(p-chlorophenoxy)-3,5-diiodosalicylanilide or a salt thereof, 3,3',5,5',6-pentachloro-2,2'-dihydroxybenzanilide or a salt thereof, methyl 1-butylcarbomoyl)benzimidazole-2-carbamate, methyl benzimidazole-2-carbamate, diethyl 4,4'-o-phenylenebis(3-thioallophanate, methyl 5-propoxybenzimidazole-2-carbamate, triphenylbismuth triphenylbismuth dinitrate, triphenylbismuth dichloride, triphenylbismuth difluoride, 4.
Claim 5
Dependent Claim
7 words
5,6-trichloro-7-(diethylsulphamoyl)-2-(trifluoromethyl)benzimidazole, 4-bromo-5,6-dichloro-7-(diethylsulphamoyl)-2-(trifluoromethyl)benzimidazole 4,5,6-tribromo-7-(diethylsulphamoyl-2-(trifluoromethyl)benzimidazole, 4,6-dibromo-5-chloro-7-(diethylsulphamoyl)-2-(trifluoromethyl)benzimidazole 4,5,6-trichloro-7-(ethylsulphamoyl)-2-(trifluoromethyl)benzimidazole; 4,5,6-trichloro-7-(methylsulphamoyl)-2-(trifluoromethyl)benzimidazole, 4,5,6-trichloro-7-(n-propylsulphamoyl)-2-(trifluoromethyl)benzimidazole,
Claim 6
Dependent Claim
7 words
5,6-trichloro-7-(diethylsulphamoyl)-2-(trifluoromethyl)benzimidazole, 4-bromo-5,6-dichloro-7-(diethylsulphamoyl)-2-(trifluoromethyl)benzimidazole 4,5,6-tribromo-7-(diethylsulphamoyl-2-(trifluoromethyl)benzimidazole, 4,6-dibromo-5-chloro-7-(diethylsulphamoyl)-2-(trifluoromethyl)benzimidazole 4,5,6-trichloro-7-(ethylsulphamoyl)-2-(trifluoromethyl)benzimidazole; 4,5,6-trichloro-7-(methylsulphamoyl)-2-(trifluoromethyl)benzimidazole, 4,5,6-trichloro-7-(n-propylsulphamoyl)-2-(trifluoromethyl)benzimidazole,
Claim 7
Dependent Claim
18 words
and salts of said benzimidazoles. 4. A method according to claim 3, wherein the anthelmintic compound is laevo-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-05-30 | 1980-11-29 | 1981-05-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-05-30 | 1984-11-29 | 1985-05-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-05-30 | 1988-11-29 | 1989-05-31 | $7700.00 | Window Closed / Lapsed |